Radiopharm Theranostics Ltd (RADX) Total Current Liabilities (2024 - 2026)

Radiopharm Theranostics (RADX) has reported Total Current Liabilities for 3 consecutive years, with $134046.3 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 40.16% year-over-year to $134046.3 in Q2 2026; TTM through Jun 2026 was $134046.3, a 40.16% increase from a year earlier, with the FY2026 full-year figure at $128340.6, down 99.14% from the prior year.
• Total Current Liabilities was $134046.3 for Q2 2026 at Radiopharm Theranostics, up from $95635.8 in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.1 million in Q4 2024 and troughed at $95635.8 in Q2 2025.
• A 3-year average of $3.4 million and a median of $124937.4 in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities retreated 17.43% in 2025 and jumped 40.16% in 2026, its largest moves.
• Over 3 years, Total Current Liabilities stood at $13.1 million in 2024, then sank by 99.27% to $95635.8 in 2025, then surged by 40.16% to $134046.3 in 2026.
• The last three Total Current Liabilities figures came in at $134046.3 (Q2 2026), $95635.8 (Q2 2025), and $13.1 million (Q4 2024), per Business Quant data.